[January 29, 2016]

Global Cancer Pain Therapeutics Market 2015-2019 - Key Vendors are BioDelivery Sciences, ProStrakan Group, Teva Pharmaceuticals & Yamaha - Research and Markets

Research and Markets (http://www.researchandmarkets.com/research/36pfgs/global_cancer) has announced the addition of the "Global Cancer Pain Therapeutics Market 2015-2019" report to their offering.

The report forecasts the global cancer pain therapeutics market to grow at a CAGR of 9.08% during the period 2016-2020.

To overcome the severe competition being posed, the key players and other vendors have started differentiating their drugs in an attempt to increase profits and avoid price competition. According to the report, the major driving factor for the global cancer pain therapeutics market is the high unmet need for appropriate drugs in the market.

Further, the report states that the use of off-label drugs is another important challenge for the market.

Key questions answered in this report:

• What will the market size be in 2020 and what will the growth rae be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
  
  
  
  

Companies Mentioned:

• BioDelivery Sciences
• ProStrakan Group
• Teva Pharmaceuticals
• Daiichi Sankyo
• Eli-lilly
• Galena Biopharma
• Grunenthal Group
• GW Pharmaceuticals
• Hospira
• Johnson & Johnson
• Meda Pharmaceuticals
• Orexo
• Sanofi
• Sorrento Therapeutics
• WEX Pharmaceuticals.

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Market research methodology

PART 04: Introduction

PART 05: Disease overview

PART 06: Pipeline portfolio

PART 07: Market landscape

PART 08: Market segmentation by drug class

PART 09: Geographical segmentation

PART 10: Market drivers

PART 11: Impact of drivers

PART 12: Market challenges

PART 13: Impact of drivers and challenges

PART 14: Market trends

PART 15: Vendor landscape

PART 16: Vendor landscape

PART 17: Key vendor analysis

PART 18: Appendix

For more information visit http://www.researchandmarkets.com/research/36pfgs/global_cancer

View source version on businesswire.com: http://www.businesswire.com/news/home/20160129005457/en/

[ Back To TMCnet.com's Homepage ]